

RealRate

PHARMACEUTICAL 2017

ZOGENIX INC. Rank 32 of 292







PHARMACEUTICAL 2017

ZOGENIX INC. Rank 32 of 292

The relative strengths and weaknesses of ZOGENIX INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ZOGENIX INC. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 64% points. The greatest weakness of ZOGENIX INC. is the variable Other Expenses, reducing the Economic Capital Ratio by 9.7% points.

The company's Economic Capital Ratio, given in the ranking table, is 233%, being 230% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	119,914
Cost of Goods Sold	0
Intangible Assets	108,734
Liabilities, Current	20,310
Liabilities, Non-Current	0
Other Assets	1,147
Other Compr. Net Income	0
Other Expenses	31,751
Other Liabilities	0
Other Net Income	2,030
Other Revenues	28,850
Property and Equipment	1,710
Research and Development	41,840
Selling, General and Administrative Expense	26,996

Output Variable	Value in 1000 USD
Assets	231,505
Liabilities	20,310
Expenses	100,587
Revenues	28,850
Stockholders Equity	211,195
Net Income	-69,707
Comprehensive Net Income	-69,707
Economic Capital Ratio	233%

